COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04442126
Recruitment Status : Recruiting
First Posted : June 22, 2020
Last Update Posted : October 8, 2020
Information provided by (Responsible Party):
Numab Therapeutics AG

Brief Summary:
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Biological: NM21-1480 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 102 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Actual Study Start Date : June 30, 2020
Estimated Primary Completion Date : July 17, 2022
Estimated Study Completion Date : August 9, 2022

Arm Intervention/treatment
Experimental: NM21-1480 Treatment arm Biological: NM21-1480
Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein

Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to 3 years ]
    Frequency and severity of adverse events

  2. Maximum Tolerated Dose (MTD) of NM21-1480 [ Time Frame: Up to 3 years ]
    To determine the MTD of NM21-1480

  3. Determination of Phase 2 dose of NM21-1480 [ Time Frame: Up to 3 years ]
    To determine the recommended Phase 2 dose of NM21-1480 for Part B of the study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Part A

  • Patients with any previously treated solid tumor-type other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma that is advanced, or recurrent and progressing since last anti-tumor therapy, and for which no alternative, standard therapy exists.
  • Prior chemotherapy, radiation therapy or immunotherapy must have been completed at least 4 weeks prior to the administration of the first dose of study drug, and patient has recovered

Part B:

  • Patients with Non Small Cell Lung Cancer (NSCLC), Squamous Cell Cancer Head and Neck (SCCHN) and basket cohort consisting of melanoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma or urothelial carcinoma with locally advanced or metastatic, non-resectable disease, which has progressed despite treatment with anti-programmed cell death protein (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monotherapy or anti-PD1/chemotherapy or anti-PD-L1/chemotherapy
  • Prior therapy must have been completed at least 4 weeks prior to the administration of the first dose of study drug.

Exclusion Criteria:

  • Patient previously had known immediate or delayed hypersensitivity reaction or idiosyncrasy to the excipients
  • Treatment with any PD-1, or Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 directed antibody or with any other immunotherapy within 4 weeks prior to initiation of the study drug.
  • Part A: Use of other biological investigational drugs (drugs not marketed for any indication), including use of investigational drugs targeting CD137/4-1BB within at least 5 half-lives (or within 8 weeks, whatever is longer) prior to the administration of the first dose of study drug.
  • Part B: Use of other biological drugs (marketed or investigational) for treatment of the current cancer other than anti-PD1, anti-PD-L1, or anti-CTLA-4 directed antibodies.
  • Patient has an active autoimmune disease or a documented history of autoimmune disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04442126

Layout table for location contacts
Contact: Peter Lichtlen, MD, PhD, BBA +41-44-533-22-92

Layout table for location information
United States, Pennsylvania
UPMC Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Sarah Brodeur, BS    412-623-2944   
United States, Tennessee
Sarah Cannon Cancer Center Recruiting
Nashville, Tennessee, United States, 37203
Contact: Sheetal Champaneria         
United States, Texas
The University Of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: David S Hong, MD    713-563-5844   
National Taiwan University Hospital Not yet recruiting
Taipei, Taiwan
Contact: To be determined         
Sponsors and Collaborators
Numab Therapeutics AG
Layout table for additonal information
Responsible Party: Numab Therapeutics AG Identifier: NCT04442126    
Other Study ID Numbers: NB-ND021 (NM21-1480)-101
2020-0355 ( Other Identifier: MDACC Protocol ID )
First Posted: June 22, 2020    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms